Blood pressure reduction: An added benefit of sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes

Diabetes Care

Volumn 38, Issue 3, 2015, Pages 429-430

  Majewski, Colleen ^a   Bakris, George L ^a  

^a UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANAGLIFLOZIN; EMPAGLIFLOZIN; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; ANTIDIABETIC AGENT; BENZHYDRYL DERIVATIVE; GLUCOSIDE; SODIUM GLUCOSE COTRANSPORTER 2; THIOPHENE DERIVATIVE;

BLOOD PRESSURE REGULATION; CLINICAL EFFECTIVENESS; DIASTOLIC BLOOD PRESSURE; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; GLYCEMIC CONTROL; HUMAN; HYPERTENSION; KIDNEY FUNCTION; NON INSULIN DEPENDENT DIABETES MELLITUS; NOTE; OSMOTIC DIURESIS; PRACTICE GUIDELINE; SYSTOLIC BLOOD PRESSURE; ANTAGONISTS AND INHIBITORS; BLOOD PRESSURE; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DRUG EFFECTS; MIDDLE AGED; PATHOPHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC);

BENZHYDRYL COMPOUNDS; BLOOD PRESSURE; CANAGLIFLOZIN; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; GLUCOSIDES; HUMANS; HYPERTENSION; HYPOGLYCEMIC AGENTS; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SODIUM-GLUCOSE TRANSPORTER 2; THIOPHENES;

EID: 84962360678     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc14-1596     Document Type: Note

References (7)

1. Plosker GL. Canagliflozin: A review of its use in patients with type 2 diabetes mellitus. Drugs 2014;74:807-824.
2. Plosker GL. Dapagliflozin: A review of its use in patients with type 2 diabetes. Drugs 2014;74: 2191-2209.
3. Oliva RV, Bakris GL. Blood pressure effects of sodium-glucose co-transport 2 (SGLT2) inhibitors. J Am Soc Hypertens 2014;8:330-339.
4. Tikkanen I, Narko K, Zeller C, et al.; EMPAREG BP Investigators. Empagliflozin reduces blood pressure in patients with type 2 diabetes and hypertension. Diabetes Care 2015;38: 420-428.
5. McManus RJ, Caulfield M, Williams B; National Institute for Health and Clinical Excellence. NICE hypertension guideline 2011: Evidence based evolution. BMJ 2012;344: E181.
6. Yamout H, Perkovic V, Davies M, et al. Efficacy and safety of canagliflozin in patients with type 2 diabetes and stage 3 nephropathy. Am J Nephrol 2014;40:64-74.
7. Cherney DZ, Perkins BA, Soleymanlou N, et al. The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus. Cardiovasc Diabetol 2014;13:28.